Genetic aberration Malignancy Therapy Aberration conveys
KRAS mutation CRC Cetuximab/ Panitumumab [5] Resistance
BRAF mutation CRC Cetuximab/ Panitumumab [5] Resistance
EGFR mutation NSCLC Erlotinib/Gefitinib [7] Sensitivity
EML4_ALK translocation NSCLC Crizotinib [8] Sensitivity
BRAF mutation melanoma Vemurafenib [9] Sensitivity
cKIT mutation or amplification melanoma Imatinib/Sumitinib [10]  
BCR_ABL translocation CML Imatinib/Dasatinib [11] Sensitivity
HER2 amplification breast cancer Transtuzumab [12] Sensitivity
Table 2: Examples of biomarkers predicting response to therapy.